At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET
Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, showing statistically significant dystrophin expression and functional improvements. The company plans a Q2 2026 BLA submission for accelerated approval, with a potential U.S. launch in Q1 2027. Cash remains strong at $1.1 billion, supporting operations into Q1 2028, despite increased R&D and net losses.
- Positive topline results from DELIVER trial: 5.46% normal dystrophin expression at 6 months (7-fold increase, p<0.0001); functional improvements in TTR and 10MWR vs. placebo (nominal p<0.05).
- Z-rostudirsen safety profile remains favorable, with mostly mild-to-moderate treatment-related adverse events.
- BLA submission for z-rostudirsen planned for Q2 2026; potential U.S. launch in Q1 2027 assuming Priority Review.
- Enrollment in ACHIEVE trial for z-basivarsen in DM1 on track for completion in Q2 2026, with BLA submission expected in early Q3 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access